• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲磺酸萘莫司他在体外循环心脏手术中对血小板及凝血纤溶系统的影响。

Effects of nafamostat mesilate on platelets and coagulofibrinolysis during cardiopulmonary bypass surgery.

作者信息

Tanaka K, Kondo C, Takagi K, Sato T, Yada I, Yuasa H, Kusagawa M

机构信息

Department of Thoracic Surgery, Mie University School of Medicine, Japan.

出版信息

ASAIO J. 1993 Jul-Sep;39(3):M545-9.

PMID:8268595
Abstract

The effect of nafamostat mesilate (FUT-175) on platelet membrane glycoproteins and the coagulofibrinolytic system were analyzed. Twenty-five patients undergoing aorto-coronary bypass surgery were randomly distributed into an FUT treated group and a control group. In the control group, anticoagulation was achieved with sodium heparin (3 mg/kg) immediately before cardiopulmonary bypass (CPB). In the FUT treated group, in addition to the usual treatment with heparin, FUT-175 was infused continuously at a rate of 2 mg/kg/hr. In the control group, alpha 2 plasmin inhibitor/plasmin complex (PIC) and fibrinogen/fibrin degradation products (FDP) D-dimer increased significantly during CPB, reaching 6.1 +/- 5.1 micrograms/ml and 576 +/- 200 ng/ml, respectively, at 60 min of CPB. PIC and FDP D-dimer remained significantly lower in the FUT treated group than in the control group. GPIb on platelets decreased significantly in both groups, but remained higher in the FUT treated group (81 +/- 5% vs. 56 +/- 21% at 60 min of CPB, P < 0.01). There were no significant changes in GPIIb/IIIa on platelets throughout the procedure in either group. Blood loss after CPB was significantly lower in the FUT treated group than in the control group (778 +/- 277 ml vs. 1,342 +/- 426 ml, P < 0.01). The authors conclude that FUT-175 improves hemostasis after CPB, not only by inhibiting fibrinolysis, but also by preserving platelet GPIb during CPB.

摘要

分析了甲磺酸萘莫司他(FUT - 175)对血小板膜糖蛋白及凝血纤溶系统的影响。25例行主动脉冠状动脉搭桥手术的患者被随机分为FUT治疗组和对照组。对照组在体外循环(CPB)前即刻用肝素钠(3mg/kg)进行抗凝。在FUT治疗组中,除了常规肝素治疗外,FUT - 175以2mg/kg/小时的速率持续输注。在对照组中,CPB期间α2纤溶酶抑制剂/纤溶酶复合物(PIC)和纤维蛋白原/纤维蛋白降解产物(FDP)D - 二聚体显著增加,在CPB 60分钟时分别达到6.1±5.1微克/毫升和576±200纳克/毫升。FUT治疗组的PIC和FDP D - 二聚体仍显著低于对照组。两组血小板上的糖蛋白Ib(GPIb)均显著降低,但FUT治疗组仍较高(CPB 60分钟时为81±5%对56±21%,P<0.01)。两组在整个过程中血小板上的糖蛋白IIb/IIIa(GPIIb/IIIa)均无显著变化。FUT治疗组CPB后的失血量显著低于对照组(778±277毫升对1342±426毫升,P<0.01)。作者得出结论,FUT - 175不仅通过抑制纤溶,还通过在CPB期间保留血小板GPIb来改善CPB后的止血。

相似文献

1
Effects of nafamostat mesilate on platelets and coagulofibrinolysis during cardiopulmonary bypass surgery.甲磺酸萘莫司他在体外循环心脏手术中对血小板及凝血纤溶系统的影响。
ASAIO J. 1993 Jul-Sep;39(3):M545-9.
2
Nafamostat mesilate administration during cardiopulmonary bypass decreases postoperative bleeding after cardiac surgery.在体外循环期间给予甲磺酸萘莫司他可减少心脏手术后的术后出血。
ASAIO Trans. 1991 Jul-Sep;37(3):M194-5.
3
Nafamostat mesilate reduces blood loss during open heart surgery.
Circulation. 1993 Nov;88(5 Pt 2):II432-6.
4
[Experimental study on heparin-free cardiopulmonary bypass using nafamostat mesilate (FUT-175) and heparin-coated circuit].
Nihon Kyobu Geka Gakkai Zasshi. 1993 Nov;41(11):2166-73.
5
Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.甲磺酸萘莫司他和最小剂量抑肽酶对体外循环中血液与异物表面相互作用的影响。
Ann Thorac Surg. 2004 Feb;77(2):644-50. doi: 10.1016/S0003-4975(03)01513-3.
6
Nafamostat mesilate reduces blood-foreign surface reactions similar to biocompatible materials.
Ann Thorac Surg. 1996 Nov;62(5):1404-11. doi: 10.1016/0003-4975(96)00634-0.
7
Coagulation and fibrinolysis system in aortic surgery under deep hypothermic circulatory arrest with aprotinin: the importance of adequate heparinization.抑肽酶用于深低温停循环主动脉手术中的凝血与纤溶系统:充分肝素化的重要性
Circulation. 1997 Nov 4;96(9 Suppl):II-376-81.
8
Platelet dysfunction during cardiopulmonary bypass surgery. With special reference to platelet membrane glycoproteins.体外循环心脏手术期间的血小板功能障碍。特别提及血小板膜糖蛋白。
ASAIO J. 1993 Jul-Sep;39(3):M550-3.
9
Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting?体外循环是冠状动脉旁路移植术后阿司匹林抵抗的一个原因吗?
Eur J Cardiothorac Surg. 2005 Apr;27(4):606-10. doi: 10.1016/j.ejcts.2004.12.010. Epub 2005 Jan 19.
10
The use of minimized extracorporeal circulation system has a beneficial effect on hemostasis--a randomized clinical study.最小化体外循环系统的应用对止血有有益作用——一项随机临床研究。
Heart Surg Forum. 2006;9(1):E543-8. doi: 10.1532/HSF98.20051110.

引用本文的文献

1
Management of cardiopulmonary bypass in patients with ischemic and hemorrhagic strokes in surgery for active infective endocarditis.活动性感染性心内膜炎手术中合并缺血性和出血性卒中患者的体外循环管理
Indian J Thorac Cardiovasc Surg. 2024 May;40(Suppl 1):61-68. doi: 10.1007/s12055-023-01642-0. Epub 2023 Dec 19.
2
A benefit-risk review of systemic haemostatic agents: part 1: in major surgery.全身性止血剂的获益-风险评估:第1部分:在大手术中
Drug Saf. 2008;31(3):217-30. doi: 10.2165/00002018-200831030-00003.
3
Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery.
降低手术患者输血需求的药理学策略。
Drugs. 2002;62(15):2193-211. doi: 10.2165/00003495-200262150-00003.